Comparative Pharmacology
Head-to-head clinical analysis: ALVESCO versus VANCERIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVESCO versus VANCERIL.
ALVESCO vs VANCERIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine production in the airways.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
2 inhalations (84 mcg) 3-4 times daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Terminal elimination half-life is approximately 2.8 hours in adults; prolonged in patients with hepatic impairment.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Primarily hepatic metabolism; <10% excreted unchanged in urine, <5% in feces.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid